| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Arch Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$0.80 |
| 52 Week Low | US$0.80 |
| Beta | 3.43 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HHJ | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -0.3% |
| 1Y | n/a | 10.1% | 9.8% |
Return vs Industry: Insufficient data to determine how 0HHJ performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how 0HHJ performed against the UK Market.
Price Volatility
| 0HHJ volatility | |
|---|---|
| 0HHJ Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HHJ has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0HHJ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 8 | Terrence Norchi | www.archtherapeutics.com |
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds.
Arch Therapeutics, Inc. Fundamentals Summary
| 0HHJ fundamental statistics | |
|---|---|
| Market cap | US$14.85m |
| Earnings (TTM) | -US$6.41m |
| Revenue (TTM) | US$37.77k |
393.1x
P/S Ratio-2.3x
P/E RatioIs 0HHJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HHJ income statement (TTM) | |
|---|---|
| Revenue | US$37.77k |
| Cost of Revenue | US$55.01k |
| Gross Profit | -US$17.23k |
| Other Expenses | US$6.40m |
| Earnings | -US$6.41m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.35 |
| Gross Margin | -45.63% |
| Net Profit Margin | -16,980.91% |
| Debt/Equity Ratio | -75.9% |
How did 0HHJ perform over the long term?
See historical performance and comparison